I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Rory Riggs Biography and Net Worth

Director of Royalty Pharma

Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of chairman in 2003. Mr. Riggs is the founder & CEO of Syntax & Locus Analytics. Previously, Mr. Riggs was President of Biomatrix. Mr. Riggs serves or has served on several boards including Fibrogen, Cibus, Sugen, Intra-cellular Therapies and Biomatrix. Mr. Riggs has a BA from Middlebury College and an MBA from Columbia University.

What is Rory B. Riggs' net worth?: The estimated net worth of Rory B. Riggs is at least $2.96 million as of June 24th, 2024. Mr. Riggs owns 116,600 shares of Royalty Pharma stock worth more than $2,958,142 as of December 30th. This net worth approximation does not reflect any other investments that Mr. Riggs may own. Learn More about Rory B. Riggs' net worth.
How do I contact Rory B. Riggs?: The corporate mailing address for Mr. Riggs and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Rory B. Riggs' contact information.
Has Rory B. Riggs been buying or selling shares of Royalty Pharma?: Rory B. Riggs has not been actively trading shares of Royalty Pharma within the last three months. Most recently, Rory B. Riggs sold 35,702 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $27.55, for a transaction totalling $983,590.10. Following the completion of the sale, the director now directly owns 20,099 shares of the company's stock, valued at $553,727.45. Learn More on Rory B. Riggs' trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 270,902 shares worth more than $7,691,494.10. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Rory B. Riggs Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/4/2024	Sell	35,702	$27.55	$983,590.10	20,099
1/2/2024	Sell	235,200	$28.52	$6,707,904.00	254,899
5/22/2023	Sell	1,750,000	$32.82	$57,435,000.00	6,762
3/29/2023	Sell	9,926	$36.95	$366,765.70	1,586,786
12/12/2022	Sell	40,010	$41.98	$1,679,619.80	96,712
12/9/2022	Sell	19,990	$42.07	$840,979.30	136,722
11/17/2022	Sell	120,000	$42.33	$5,079,600.00	156,712
9/14/2022	Sell	47,975	$42.41	$2,034,619.75	328,737
8/9/2022	Sell	45,000	$43.73	$1,967,850.00	376,712
6/29/2022	Sell	30,000	$42.17	$1,265,100.00	421,712
5/19/2022	Sell	26,304	$40.09	$1,054,527.36	575,408
3/29/2022	Sell	60,000	$38.59	$2,315,400.00
3/21/2022	Sell	39,867	$39.05	$1,556,806.35
3/18/2022	Sell	129,222	$39.55	$5,110,730.10
12/28/2021	Sell	109,448	$40.21	$4,400,904.08
11/16/2021	Sell	12,565	$42.01	$527,855.65
9/28/2021	Sell	40,000	$36.75	$1,470,000.00
6/28/2021	Sell	167,448	$42.11	$7,051,235.28	679,760
6/25/2021	Sell	666,464	$42.72	$28,471,342.08	679,760
10/20/2020	Sell	463,200	$42.00	$19,454,400.00	463,200

Rory B. Riggs Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $25.37

$25.18

$25.50

50 Day Range

MA: $26.16

$24.28

$27.75

2 Week Range

Now: $25.37

$24.05

$31.66

Volume

584,325 shs

Average Volume

2,681,482 shs

Market Capitalization

$14.95 billion

P/E Ratio

13.15

Dividend Yield

3.33%

Beta

0.46

3 CENT Crypto to Explode December 16th?

From True Market Insiders | Ad

Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…

#1 FREE Crypto for 2025